These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 2975220)

  • 1. Hormonal pattern and testicular histology in patients with prostatic cancer after long-term treatment with a gonadotropin-releasing hormone agonist analogue.
    Giberti C; Barreca T; Martorana G; Truini M; Franceschini R; Rolandi E; Giuliani L
    Eur Urol; 1988; 15(1-2):125-7. PubMed ID: 2975220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained impairment of pituitary and testicular function in prostatic cancer patients treated with a depot form of a GnRH agonist.
    Rolandi E; Franceschini R; Giberti C; Brancadoro T; Martorana G; Barreca T
    Horm Res; 1988; 30(1):22-5. PubMed ID: 2975631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence for testicular impairment after long-term treatment with a luteinizing hormone-releasing hormone agonist in elderly men.
    Decensi AU; Guarneri D; Marroni P; Di Cristina L; Paganuzzi M; Boccardo F
    J Urol; 1989 Nov; 142(5):1235-8. PubMed ID: 2530360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Testicular histology following chronic gonadotropin-releasing hormone agonist treatment.
    Rajfer J; Swerdloff RS; Heber DM
    Fertil Steril; 1984 Nov; 42(5):765-71. PubMed ID: 6436070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Testicular histology after prolonged treatment with a gonadotropin-releasing hormone analogue.
    Smith JA; Urry RL
    J Urol; 1985 Apr; 133(4):612-4. PubMed ID: 3920405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of prostatic cancer with a depot form of a luteinizing hormone-releasing hormone analogue.
    Giuliani L; Barreca T; Giberti C; Franceschini R; Martorana G; Brancadoro MT; Salvemini M; Rolandi E
    Eur Urol; 1986; 12(6):390-4. PubMed ID: 2949979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective effects of analogs of luteinizing hormone-releasing hormone against chemotherapy-induced testicular damage in rats.
    Karashima T; Zalatnai A; Schally AV
    Proc Natl Acad Sci U S A; 1988 Apr; 85(7):2329-33. PubMed ID: 2965391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Germinal cell aplasia: response of luteinizing hormone (LH), follicle-stimulating hormone (FSH), and testosterone to LH/FSH-releasing hormone with histopathologic correlation.
    Guay AT; Tuthill RJ; Woolf PD
    Fertil Steril; 1977 Jun; 28(6):642-9. PubMed ID: 324822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term results with a long-acting formulation of D-TRP-6 LH-RH in patients with prostate cancer: an Italian prostatic cancer project (P.O.N.CA.P.) study.
    Boccardo F; Decensi A; Guarneri D; Rubagotti A; Massa T; Martorana G; Giberti C; Cerruti GB; Tani F; Zanollo A
    Prostate; 1987; 11(3):243-55. PubMed ID: 2960957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How would you like to have an orchidectomy for advanced prostatic cancer?
    Parmar H; Phillips RH; Lightman SL; Edwards L
    Am J Clin Oncol; 1988; 11 Suppl 2():S160-8. PubMed ID: 2977271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of the pituitary-gonadal axis by a single intramuscular administration of D-Trp-6-LH-RH (decapeptyl) in a sustained-release formulation in patients with prostatic carcinoma.
    Gonzalez-Barcena D; Perez-Sanchez PL; Graef A; Gomez AM; Berea H; Comaru-Schally AM; Schally AV
    Prostate; 1989; 14(4):291-300. PubMed ID: 2526325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effects of a short course of neoadjuvant luteinizing hormone-releasing hormone analogue and radical radiotherapy on the hormonal profile in patients with localized prostate cancer.
    Murthy V; Norman AR; Barbachano Y; Parker CC; Dearnaley DP
    BJU Int; 2007 Jun; 99(6):1380-2. PubMed ID: 17537213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective effects of analogs of luteinizing hormone-releasing hormone against x-radiation-induced testicular damage in rats.
    Schally AV; Paz-Bouza JI; Schlosser JV; Karashima T; Debeljuk L; Gandle B; Sampson M
    Proc Natl Acad Sci U S A; 1987 Feb; 84(3):851-5. PubMed ID: 2949328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gonadotropin-independent familial sexual precocity with premature Leydig and germinal cell maturation (familial testotoxicosis): effects of a potent luteinizing hormone-releasing factor agonist and medroxyprogesterone acetate therapy in four cases.
    Rosenthal SM; Grumbach MM; Kaplan SL
    J Clin Endocrinol Metab; 1983 Sep; 57(3):571-9. PubMed ID: 6223935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of synthetic agonist analogue of gonadotropin-releasing hormone (leuprolide) on testicular androgen production in patients with carcinoma of prostate.
    Santen RJ; Warner B
    Urology; 1985 Feb; 25(2 Suppl):53-7. PubMed ID: 3918377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of testicular androgenesis by D-tryptophan-6-luteinizing hormone-releasing hormone does not affect TSH secretion in male subjects.
    Barreca T; Martorana G; Franceschini R; Giberti C; Brancadoro MT; Messina V; Rolandi E
    Horm Res; 1986; 23(3):181-4. PubMed ID: 2936667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term effect of D-Trp6-luteinizing hormone-releasing hormone on testicular size and luteinizing hormone, follicle-stimulating hormone, and testosterone levels in hypothalamic hypogonadotropic males.
    Laron Z; Dickerman Z; Ben Zeev Z; Prager-Lewin R; Comaru-Schally AM; Schally AV
    Fertil Steril; 1981 Mar; 35(3):328-31. PubMed ID: 6781940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of prostate tumor growth in two rat models by chronic administration of D-Trp6 analogue of luteinizing hormone-releasing hormone.
    Redding TW; Schally AV
    Proc Natl Acad Sci U S A; 1981 Oct; 78(10):6509-12. PubMed ID: 6458815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
    Kaku H; Saika T; Tsushima T; Ebara S; Senoh T; Yamato T; Nasu Y; Kumon H
    Prostate; 2006 Mar; 66(4):439-44. PubMed ID: 16329145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial with D-Trp-6-LH-RH in prostatic carcinoma: comparison with other hormonal agents.
    Mathé G; Schally AV; Comaru-Schally AM; Mauvernay RY; Vovan ML; Machover D; Misset JL; Court B; Bouchard P; Duchier J
    Prostate; 1986; 9(4):327-42. PubMed ID: 2947053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.